Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. (Q34996698)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Paul A Meyers

series ordinal

1

1 reference

5 August 2017

publication date

1 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

1035-1049

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

Management of osteosarcoma

5 February 2020

cites work

1 reference

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

21 January 2018

1 reference

Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment

21 January 2018

1 reference

Spontaneously occurring tumors of companion animals as models for human cancer

21 January 2018

1 reference

Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide

21 January 2018

1 reference

Post operative infection and increased survival in osteosarcoma patients: are they associated?

21 January 2018

1 reference

Signalling pathways and molecular interactions of NOD1 and NOD2

21 January 2018

1 reference

Nod1 and Nod2 in innate immunity and human inflammatory disorders

21 January 2018

1 reference

Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection

21 January 2018

1 reference

Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease

21 January 2018

1 reference

Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide

21 January 2018

1 reference

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma

21 January 2018

1 reference

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration

21 January 2018

1 reference

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma

21 January 2018

1 reference

Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells

21 January 2018

1 reference

Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides

21 January 2018

1 reference

Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat

21 January 2018

1 reference

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review

21 January 2018

1 reference

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?

21 January 2018

1 reference

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

21 January 2018

1 reference

Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update

21 January 2018

1 reference

Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study

21 January 2018

1 reference

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

21 January 2018

1 reference

Osteosarcoma: the same old drugs or more?

21 January 2018

1 reference

Complexities in interpretation of osteosarcoma clinical trial results.

21 January 2018

1 reference

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases

21 January 2018

1 reference

Zoledronic acid inhibits osteosarcoma growth in an orthotopic model

21 January 2018

1 reference

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19671023%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference